所长
邵志敏 教授
教授,博士生导师
E-mail: zhimingshao@yahoo.com
 

  邵志敏教授,首批教育部长江学者特聘教授,复旦特聘教授。现任复旦大学肿瘤研究所所长,乳腺癌研究所所长,大外科主任兼乳腺外科主任,中国抗癌协会乳腺癌专业委员会常委,中华医学会肿瘤学分会副主任委员,中国医师协会临床精准医疗专业委员会乳腺癌专业委员会主委,上海市抗癌协会乳腺癌专业委员会名誉主任委员,上海市医学会肿瘤专科委员会主任委员,第八届亚洲乳腺癌协会主席,St. Gallen乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,开展临床试验提高乳腺癌患者的预后,科研重点为乳腺癌的转化研究和乳腺癌转移机制研究等。已发表有关乳腺癌研究的论著近350篇,其中SCI收录100余篇,被世界医学文献引用逾3000次,主编专著4本。并多次获得卫生部科技进步一等奖,上海市科技进步一、二、三等奖,国家科技进步二等奖,教育部科技进步一、二等奖,领衔团队分别入选教育部创新团队、上海市乳腺肿瘤重点实验室及上海市教委“重中之重临床医学中心B类”项目、上海市重要疾病联合攻关项目。先后主持国家杰青基金、国自然、十五攻关课题、卫生部临床重点项目、211工程II、985、973课题及其他省部级项目30余项。


研究领域:

  主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,开展临床试验提高乳腺癌患者的预后;科研重点为乳腺癌的转化研究和乳腺癌转移机制研究等。

研究团队:



代表性论著:

  1. Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD, Shao ZM*. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res, 2016 Apr 15; 76(8):2105-14.
  2. Liu YR, Jiang YZ, Xu XE, Hu X, Yu KD, Shao ZM*. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clin Cancer Res, 2016 Apr 1; 22(7):1653-62.
  3. Liu YR, Jiang YZ, Xu XE, Yu KD, Jin X, Hu X, Zuo WJ, Hao S, Wu J, Liu GY, Di GH, Li DQ, He XH, Hu WG, Shao ZM*. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res, 2016 Mar 15; 18(1):33.
  4. Zuo WJ, Jiang YZ, Wang YJ, Xu XE, Hu X, Liu GY, Wu J, Di GH, Yu KD, Shao ZM*. Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clin Cancer Res, 2016 Oct 1; 22(19):4859-4869.
  5. Jiang YZ, Yu KD, Bao J, Peng WT, Shao ZM*. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. Cancer Res, 2014 Jul 1; 74(13):3399-407.
  6. Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, Shao ZM*. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat Commun, 2014 May 13; 5:3802.
  7. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM*, Goss PE. Breast cancer in China. Lancet Oncol, 2014 Jun; 15(7):e279-89.
  8. Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, Wu J, Shen ZZ, Song HY, Shao ZM*. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res, 2013 Mar 15; 19(6):1389-99.
  9. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res, 2013 May 15; 19(10):2723-33.
  10. Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, Zhi-Ming Shao*. The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy. Clin Cancer Res, 2013 Dec 15; 19(24):6853-62. 
  11. Yu KD, Wu J, Shen ZZ, Shao ZM*. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab, 2012 Dec; 97(12):E2201-9. 
  12. Yu KD, Shao ZM*. Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer. Nat Rev Cancer, 2012 May 24; 12(5):372-3.
  13. Yu KD, Huang AJ, Fan L, Li WF, Shao ZM*. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res, 2012 Jan 15; 72(2):408-19. 
  14. Jin W, Chen BB, Li JY, Zhu H, Huang M, Gu SM, Wang QQ, Chen JY, Yu S, Wu J, Shao ZM*. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol Cell Biol, 2012 Jan; 32(1):50-63.
  15. Chen AX, Yu KD, Fan L, Li JY, Yang C, Huang AJ, Shao ZM*. Germline genetic variants disturbing the Let-7/LIN28 double-negative feedback loop alter breast cancer susceptibility. PLoS Genet, 2011 Sep; 7(9):e1002259.
  16. Liu ZB, Hou YF, Zhu J, Hu DL, Jin W, Ou ZL, Di GH, Wu J, Shen ZZ, Shao ZM*. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene, 2010 May 20; 29(20):2996-3009.
  17. Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM*. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res, 2009 May 1; 15(9):2962-70. 
  18. Yu KD, Di GH, Yuan WT, Fan L, Wu J, Hu Z, Shen ZZ, Zheng Y, Huang W, Shao ZM*. Functional polymorphisms, altered gene expression and genetic association link NRH: quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet, 2009 Jul 1; 18(13):2502-17.
  19. Feng LY, Ou ZL, Wu FY, Shen ZZ and Shao ZM*. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res, 2009; 15: 2962-2970.
  20. Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J and Shao ZM*. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene, 2006 Nov 16; 25(54):7201-11.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有